Pharmaceuticals, Biotechnology and Life Sciences
AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), said Wednesday that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington’s Disease (HD) were published in the peer-reviewed journal Neurobiology of Disease.
CordenPharma has announced Tuesday its extended agreement with Moderna in its supply of lipids to support the development of Coronavirus Vaccine.
Comar, a premier healthcare plastic packaging, device and component supplier, is pleased to announce a major capacity expansion of our Buena plant operations by building a new offsite location in Vineland, New Jersey.
CytoSMART Technologies today announced the launch of a new live-cell imaging system. The CytoSMART Lux2 Duo Kit offers a straightforward, cost-effective solution for researchers carrying out immediate side-by-side comparisons between cell cultures.
Regeneron Pharmaceuticals and Sanofi have shared positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE), in which the trial met both co-primary endpoints.
AstraZeneca on Friday reported several clinical results from its studies, including Imfinzi and Enhertu, with meaningful outcomes.
Sanofi said Friday that Libtayo (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time.
Mylan said on Friday that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi’s Lantus® SoloSTAR® device patents, U.S. Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable.
FDA Provides Free Method to Obtain Informed Consent Electronically for Eligible Clinical Trials During the COVID-19 Public Health Emergency The…
Data from Phase III EXPAND trial, continue to build on existing clinical evidence that Mayzent has significant impact on reducing the risk of disease progression, including physical disability and cognitive decline for patients with SPMS.